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Abstract
Introduction: After standard diagnostic work-up, the aetiology of acute pancreatitis remains unknown in 16–27% of cases, a
condition referred to as idiopathic acute pancreatitis (IAP). Determining the aetiology of pancreatitis is essential, as it may
direct treatment in the acute phase and guides interventions to prevent recurrent pancreatitis.
Methods: Between 2008 and 2015, patients with acute pancreatitis were registered prospectively in 19 Dutch hospitals.
Patients who had a negative initial diagnostic work-up with regard to the underlying aetiology of their pancreatitis were
labelled ‘presumed’ IAP. The aim of this study was to assess the use of diagnostic modalities and their yield to establish an
aetiology in ‘presumed’ IAP, and to assess recurrence rates both with and without treatment.
Results: Out of the 1632 registered patients, 191 patients had a first episode of ‘presumed’ IAP, of whom 176 (92%)
underwent additional diagnostic testing: CT (n¼ 124, diagnostic yield 8%), EUS (n¼ 62, yield 35%), MRI/MRCP (n¼ 56,
yield 33%), repeat ultrasound (n¼ 97, yield 21%), IgG4 (n¼ 54, yield 9%) and ERCP (n¼ 15, yield 47%). In 64 of 176 patients
(36%) an aetiological diagnosis was established, mostly biliary (n¼ 39). In 13 out of 176 of patients (7%) a neoplasm was
diagnosed. If additional diagnostic workup revealed an aetiology, the recurrence rate was lower in the treated patients than
in the patients without a definite aetiology (15% versus 43%, p¼ 0.014).
Conclusion: Additional diagnostic testing revealed an aetiology in one-third of ‘presumed’ IAP patients. The aetiology found
was mostly biliary, but occasionally neoplasms were found. Identification of an aetiology with subsequent treatment
reduced the rate of recurrence.
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Key summary
What is established knowledge on this subject?
. The aetiology of acute pancreatitis remains unknown in 16 to 27% of cases.
. Acute pancreatitis can be wrongfully classiﬁed as IAP due to an incomplete diagnostic work-up.
. The yield of the diagnostic process and its eﬀect on recurrence rates have not been previously described.
What are significant findings in this study?
. Additional diagnostic work-up can identify an aetiology one-third of ’presumed’ idiopathic pancreatitis
patients.
. Diagnostic work-up is not performed according to current guidelines in most cases.
. The aetiology most found in ’presumed’ idiopathic pancreatitis is occult biliary stones but pancreatic or
ampullary tumours are not rare.
. Especially in patients with recurrent AP, treatment of underlying aetiologies prevents further recurrences.
Introduction
Acute pancreatitis has a wide range of causes; however,
in 16–27% of patients the aetiology remains unex-
plained.1–4 The recommended minimal diagnostic
work-up in the acute setting of a ﬁrst episode of acute
pancreatitis has been summarized in the IAP/APA evi-
dence-based guidelines and should comprise at least ﬁve
elements: (1) a detailed personal history; (2) a family
history; (3) a physical examination; (4) laboratory tests
(i.e. liver enzymes, calcium, triglycerides); and (5) a
transabdominal ultrasound (TUS).5 If the aetiology
cannot be determined using this work-up, the acute
pancreatitis is classiﬁed as ‘presumed’ idiopathic acute
pancreatitis (IAP).
Several causes of acute pancreatitis cannot be reli-
ably identiﬁed with this work-up. For instance, micro-
lithiasis and biliary sludge are missed in up to 34% of
patients on TUS.6 Furthermore, rare causes with a
major impact on patients, such as a small pancreatic
carcinoma, are easily missed by TUS. If a second TUS
remains inconclusive, an endoscopic ultrasound (EUS)
is recommended as the next diagnostic step. A system-
atic review from 2015 showed that EUS may identify an
aetiology in 61% of ‘presumed’ IAP patients, mainly
microlithiasis or sludge.7 Other recent studies also con-
ﬁrm the value of EUS in the determination of a biliary
aetiology of IAP.6,8–10 In the case of a negative EUS,
further diagnostic modalities, such as magnetic reson-
ance cholangiopancreatography (MRCP) and com-
puted tomography (CT), should be considered.5
Some studies have reported on the value of MRCP
and EUS in IAP, but studies addressing the eﬃcacy of
each step in the diagnostic process are lacking.
Therefore, in this study, we evaluated the current diag-
nostic work-up of ‘presumed’ IAP and the recurrence
rate in a multicentre prospective observational cohort.
The primary aim of this study is to explore the use of
additional diagnostic modalities and associated diag-
nostic yield to identify underlying aetiologies in ‘pre-
sumed’ IAP. The secondary aims are twofold: ﬁrst,
determine the recurrence rate of acute pancreatitis
after a ﬁrst attack of ‘presumed’ IAP, and second, the
recurrence rate after treatment of underlying aetio-
logical factors.
Methods
Study design
In this study, 19 hospitals, including ﬁve university hos-
pitals and 14 large teaching hospitals, of the Dutch
Pancreatitis Study Group (DPSG) collaborated.
Between January 2008 and December 2015, nearly all
acute pancreatitis patients admitted to these 19 hos-
pitals were prospectively registered with the DPSG.
The DPSG acute pancreatitis registration is part of
four DPSG randomized controlled trials, i.e.
PYTHON-trial (approved 4/3/2008), PONCHO-trail
(approved 22/7/2010), TENSION-trial (approved
31/1/2011) and APEC-trial (approved 12/12/2012),
and consists of all patients that did not participate in
these trials.11–14 The ethical review board approved the
protocol for all four trials including the DPSG acute
pancreatitis registry. All patients gave written informed
consent prior to inclusion. This study was conducted in
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accordance with the principles of the Declaration of
Helsinki.
Study population
Acute pancreatitis was diagnosed according to the
revised Atlanta criteria.15 The patients included had
undergone the minimal diagnostic work-up for a ﬁrst
episode of acute pancreatitis.5 Any additional diagnos-
tic work-up, i.e. repeat TUS, CT, magnetic resonance
imaging (MRI)/MRCP, EUS, immunoglobulin G4
(IgG4) or endoscopic retrograde cholangiopancreato-
graphy (ERCP), was performed at the discretion of
the treating clinician. This was also the case for the
treatment strategy for the underlying aetiologies.
To classify a pancreatitis as ‘presumed’ idiopathic,
signs of any known aetiological factor had to be absent
in the initial diagnostic work-up. The following groups
were excluded:
. Patients with a biliary aetiology, deﬁned as a serum
alanine transferase (ALT)> 2upper limit of the
normal value, a common bile duct (CBD) diameter
of 8mm for age 75 and 10mm for age >75
years or gallstones and/or sludge in the gallbladder
and/or CBD on the ﬁrst TUS.16–18
. Patients drinking either more than 3 units of alcohol
each day, or more than 5 units in the 48 hours prior
to the start of abdominal pain.19,20 Patients were
also excluded when the medical records did not spe-
cify an amount of alcohol used, but treating clinician
considered an alcoholic aetiology as likely.
. Patients with a recent ERCP, recent abdominal
trauma, recent abdominal or vascular surgery or
with cystic ﬁbrosis or known autoimmune
pancreatitis.
. Patients with a family history of hereditary pancrea-
titis, i.e. known relatives with chronic or recurrent
acute pancreatitis, or with a genetic mutation asso-
ciated with hereditary pancreatitis.21
. Patients with a serum triglycerides level of
>1000mg/dl or 11.2mmol/l.22
. Patients with a serum calcium level corrected for the
serum albumin level of >12mg/dl or 3mmol/l.23
. Patients with chronic pancreatitis according to the
M-ANNHEIM criteria.24
. Patients with medication as a possible aetiology.
Medication as an aetiology was considered when
medication with a deﬁnite association with acute
pancreatitis was used (see Supplementary Table 1
online) combined with a reasonable temporal
sequence with either the start of the medication or
dosage increase one month before the onset of the
pancreatitis.25 Additionally, when patients were
using experimental medication (e.g. chemotherapy),
and the treating clinicians considered this a likely
aetiology of the pancreatitis.
. Patients with known altered anatomy of the pan-
creas, pancreatic or bile duct(s), i.e. after hepatopan-
creatobiliary surgery or a pancreas divisum.
In all the patients included in this study the above-
mentioned work-up was performed, and was negative
for any aetiological factor.
Criteria for the aetiologies found after additional diag-
nostic work-up were deﬁned according to the above
described criteria. Autoimmune pancreatitis was classiﬁed
as possible aetiological factor when one cardinal feature
of the International Consensus Diagnostic Criteria
for Autoimmune Pancreatitis established by the
International Association of Pancreatologywas present.26
Data collection
Patients were prospectively followed during the initial
episode of pancreatitis by means of regular phone calls
to the treating clinician to assess the patient’s clinical
status and treatment strategy. During follow-up, on-
site data collection was performed including: data on
the disease course, the physical examinations and
laboratory values, imaging during follow-up, data on
readmissions and on out-patient hospital visits. To
potentially identify any aetiological factor, data from
all imaging and other tests performed, for any given
indication, were collected. If patients were transferred
or referred to other hospitals, data from these admis-
sions and/or visits were also collected. Outcome meas-
ures were assessed at a minimum of two years after the
initial admission. Before analyses, all study data were
veriﬁed by two independent researchers (NH, DU).
Outcomes
The primary outcome was the use and yield of add-
itional diagnostic tests in patients in whom initial
diagnostic work-up failed to determine an aetiology
during a ﬁrst episode of acute pancreatitis. The fol-
lowing tests were included: repeat TUS, CT, MRI/
MRCP, EUS, ERCP and IgG4 testing. If multiple
aetiological factors were found, the factor for which
treatment was initiated was considered the main aeti-
ology. Minimal diagnostic work-up was deﬁned as, a
family and personal history, laboratory tests and a
TUS. Complete diagnostic work-up according to the
IAP/APA guideline was deﬁned as undergoing work-
up until an aetiology has been established or until all
possible diagnostic tests described in the guideline
were performed. The secondary outcome was the
recurrence rate of acute pancreatitis after a ﬁrst
attack of ‘presumed’ IAP.
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Statistical analysis
All analyses were performed using IBM SPSS statistics
for Macintosh version 20 (Armonk, NY: IBM Corp).
We performed a subgroup analysis in the patients with
a ﬁrst episode of IAP after initial diagnostic work-up
at admission. For every diagnostic modality, the per-
centage of utilization and the diagnostic yield was
determined individually. Diagnostic yield was
calculated for each test individually, by dividing the
number of positive tests for aetiology by the total
number of times this test was performed. The yield
was calculated for all available diagnostic modalities
with a two-sided 95% conﬁdence interval (CI).
Continuous variables are shown as means with SDs
and, in the case of a skewed distribution, as medians
with interquartile ranges (IQRs). Continuous data was
analysed using the Student’s t-test and Mann–Whitney
Acute pancreatitis
(n =1632)
Idiopathic acute
pancreatitis
(n =214)
Recurrent acute
pancreatitis
(n =23)
First episode of
“presumed” idiopathic
acute pancreatitis
(n =191)
Exclusion (n=1418)
Aetiology
Other exclusion criteria
- Biliary (n =951)
- Alcohol (n =231)
- Post-surgical (n =11)
- HPB malignancy prior to admission (n =7)
- Hereditary pancreatitis (n =2)
- Cystic fibrosis (n =1)
- Duodenal perforation (n =1)
- due to previous Whipple-procedure (n =2)
- pancreas divisum (n =1)
- stenosis of the pancreatic duct (n =1)
- <18 years old (n =2)
- Incomplete standard work-up (n =17)
- Less than 2 years of follow-up time (n =23)
- Hypercalcaemia (n =1)
- Auto-immune (n =1)
- Altered anatomy (n =4)
- Reactive pancreatitis due to intra-abdominal abcess
  (n =1)
- necrosis due to ischaemia (n =2)
- Post-ERCP pancreatitis (n =73)
- Chronic pancreatitis (n =33)
- Medication induced (n =28)
- Hypertriglyceridaemia (n =24)
- Post-surgical/ischemic pancreatitis (n =13)
Figure 1. Flow chart of patient selection.
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test. Fisher’s exact test of independence and the chi-
square test were used, as appropriate, to compare pro-
portions. A p-value< 0.05 was considered statistically
signiﬁcant.
Results
Baseline characteristics
Of the 1632 patients registered between 2008 and 2015,
1615 patients had undergone not more than the
minimal standard diagnostic work-up on admission.
Seventeen patients who did not have a TUS on admis-
sion were excluded. Of these 1615 patients, a total of
191 (12%) were diagnosed with a ﬁrst episode of ‘pre-
sumed’ IAP (Figure 1). Baseline characteristics are
shown in Table 1. Seventy-nine of the patients were
female (41%), the median age was 61 years. In total,
31 patients died during follow-up, 5 of whom during
the initial admission. Signiﬁcantly more patients with
severe systemic disease (ASA class> 2) died compared
to more healthy patients and those with mild systemic
disease (p< 0.001). None of the patients died during a
recurrent pancreatitis episode.
Diagnostic tests
Out of 191 patients with a ﬁrst episode of ‘presumed’
IAP after minimal diagnostic work-up, 176 (92%)
underwent one or more additional diagnostic tests.
Fifty-two patients underwent one additional diagnos-
tic test; the remaining 124 underwent more than one
test. Forty-one patients (22%) had a complete initial
diagnostic work-up according to the IAP/APA
guidelines.5
The number of additional tests performed and cor-
responding diagnostic yield are listed in Table 2. In 64
of 176 patients (36%), these additional tests revealed an
aetiological factor. EUS and MRI/MRCP were each
performed in one third of patients and a second TUS
was performed in 97 patients (51%). In 35 (18%)
patients, this was done with the speciﬁc aim to establish
an aetiology. ERCP was performed in 8% of patients,
mostly in patients with a clinical suspicion of CBD
stones based on laboratory values or imaging i.e.
TUS/ERS/MRCP (n¼ 5) or in patients with a sus-
pected tumour of the papilla based on EUS ﬁndings
(n¼ 4).
Recurrence rate of acute pancreatitis
During a median follow-up of 4 years (IQR 3–6), 50 out
of 191 patients (26%) had at least one recurrence, 26 of
whom had more than one recurrent episode. In the
recurrent pancreatitis group, there were 101 recurrences
with a median of two per patient (IQR 1–2).
Out of 141 patients with a single episode of ‘pre-
sumed’ IAP, 128 patients underwent additional diag-
nostic testing. In 35 cases (27%), an aetiology was
found.
Of the 50 patients with recurrent episodes of acute
pancreatitis, an aetiological factor was identiﬁed after
additional testing in 29 patients (58%). The diagnostic
yield of additional work-up is speciﬁed for the single
episode group and the recurrent pancreatitis group in
Tables 3 and 4.
Table 1. Baseline characteristics of patients with first episode of
‘presumed’ idiopathic pancreatitis.
n¼ 191
Age in years – median (IQR$) 61 (52–72)
Female sex – no. (%) 79 (41%)
ASA score on admission ^
ASA I – no. (%) 62 (32%)
ASA II – no. (%) 82 (43%)
ASA III – no. (%) 46 (24%)
ASA IV – no. (%) 1 (1%)
BMIþ (n¼ 60, 31%) – median (IQR) 27 (25–30)
Medical history
Cardiac comorbidity – no. (%) 102 (53%)
Pulmonary comorbidity – no. (%) 19 (10%)
Chronic renal failure – no. (%) 8 (4%)
Diabetes – no. (%) 26 (14%)
Cholecystectomy prior to IAP – no. (%) 19 (10%)
Smoking (n¼ 141, 74%) – no. (%) 40 (21%)
Laboratory tests
Lipase in U/l (n¼ 112, 59%) –
median (IQR)
2078 (509–5480)
Amylase in U/l (n¼ 168, 88%) –
median (IQR)
1398 (407–2516)
ALT# in U/l – median (IQR) 26 (21–37)
AST& in U/l – median (IQR) 26 (21–37)
Bilirubin in mmol/l – median (IQR) 10 (7–17)
Triglycerides in mmol/l
(n¼ 141, 74%) – median (IQR)
1.3 (0.8–1.7)
Calcium (n¼ 179, 94%) in
mmol/l – median (IQR)
2.3 (2.2–2.4)
Mortality – no. (%) 31 (16%)
during index admission – no. (%) 5 (3%)
Follow-up time in years – median (IQR) 4 (3–6)
$IQR¼ interquartile range, ^ ASA score: American Society of
Anesthesiologists physical status classification system, I¼ a normal healthy
patient, II¼mild systemic disease, III¼ severe systemic disease,
IV¼ severe systemic disease that is a constant threat to life, þBMI¼ body
mass index, #ALT¼alanine transaminase, &AST¼aspartate transaminase.
Note: data was available for all 191 patients unless differently specified
behind the characteristic.
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Aetiological factors
In Tables 5 and 6, all aetiological factors found in both
the single episode group and the recurrent pancreatitis
group are shown. In the total of 191 patients, the most
frequent aetiological factor was biliary stones in 39
patients (20%). The percentage of patients in whom
an aetiology was detected was twice as high in patients
with recurrent pancreatitis as in patients with only one
pancreatitis attack (58% versus 27%, p¼ 0.00).
In 13 out of 191 of patients (7%), additional testing
revealed an ampullary or pancreatic neoplasm. With
seven out of 141 patients in the single episode group
(5%) versus six out of 50 in the recurrent acute pan-
creatitis group (12%), neoplasms were signiﬁcantly
more common in the recurrent acute pancreatitis
group (p¼ 0.043). Five patients were shown to have
chronic pancreatitis. Serum IgG4 testing was per-
formed in 54 patients (28%), ﬁve of whom had levels
of 2 times the upper limit of normal (ULN) or higher.
Table 2. Overview of number and yield of diagnostic tests in all patients (n¼ 191).
Test
Patients with
diagnostic
test – no. (%)
Patients with
aetiology based on
diagnostic test – no. (%)
Total of
diagnostic tests
performed – no.
Total times an
aetiology was
demonstrated – no.
Diagnostic
yield – percentage
(95% CI)
CT 124 (65%) 23 (19%) 456 35 8% (6–11)
Repeat TUS 97 (51%) 28 (29%) 195 40 21% (15–27)
EUS 62 (32%) 27 (44%) 91 32 35% (25–45)
MRCP/MRI 56 (29%) 19 (34%) 84 28 33% (23–43)
ERCP 15 (8%) 7 (47%) 18 8 44% (21–67)
IgG4 54 (28%) 5 (9%) 54 5 9% (1–16)
CT: computed tomography, TUS: transabdominal ultrasound, EUS: endoscopic ultrasound, MRCP: magnetic resonance cholangiopancreatography, MRI:
magnetic resonance imaging, ERCP: endoscopic retrograde cholangiopancreatography, IgG4: immunoglobulin G4.
Table 3. Diagnostic yield of additional diagnostic work-up in the single episode group (n¼ 141).
Test
Patients with
diagnostic
test – no. (%)
Patients with
aetiology based on
diagnostic test – no. (%)
Total of
diagnostic tests
performed – no.
Total times
an aetiology was
demonstrated – no.
Diagnostic
yield – percentage
(95% CI)
CT 88 (62%) 9 (10%) 294 11 4% (2–6)
Repeat TUS 59 (42%) 12 (20%) 113 14 12% (6–18)
EUS 36 (26%) 13 (36%) 39 14 36% (21–51)
MRCP/MRI 29 (21%) 8 (28%) 43 13 30% (16–44)
ERCP 9 (6%) 5 (56%) 12 6 50% (22–78)
IgG4 30 (21%) 4 (13%) 30 4 13% (1–25)
Table 4. Diagnostic yield of additional diagnostic work-up in the recurrent pancreatitis group (n¼ 50).
Test
Patients with
diagnostic
test – no. (%)
Patients with
aetiology based on
diagnostic test – no. (%)
Total of
diagnostic tests
performed – no.
Total times an
aetiology was
demonstrated – no.
Diagnostic
yield – percentage
(95% CI)
CT 36 (72%) 13 (36%) 162 24 15% (10–16)
Repeat TUS 38 (76%) 16 (42%) 80 26 33% (23–43)
EUS 26 (52%) 14 (54%) 52 18 35% (22–48)
MRCP/MRI 23 (46%) 11 (48%) 43 15 35% (21–49)
ERCP 6 (12%) 2 (33%) 6 2 33% (5–71)
IgG4 24 (48%) 1 (4%) 24 1 4% (3–12)
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Two patients were treated with prednisone with good
clinical response, one of which had characteristic ﬁnd-
ings of autoimmune pancreatitis on MRI. The other
three patients had no signs of autoimmune pancreatitis
on imaging and did not receive treatment. One of these
patients did have a history of ulcerative colitis and had
one recurrent episode; the other patient did not have
any recurrences. In one patient autoimmune pancrea-
titis was diagnosed, after six recurrences, in the path-
ology sample of a pancreatic mass. No serum IgG4
levels of this patient were available. None of the
patients were diagnosed with IgG4-negative auto-
immune pancreatitis.
Treatment of aetiological factors
Underlying aetiological factors were treated in 34 out
of 64 patients in whom an aetiology was found. The
other 30 patients did not receive any treatment for
underlying aetiologies.
In the treated group, the treatments performed for
underlying aetiological factors were the following:
cholecystectomy with/without ERCP with sphincterot-
omy (n¼ 22), only ERCP with sphincterotomy (n¼ 3),
prednisone treatment (n¼ 2), pylorus preserving pan-
creatoduodectomy (n¼ 4), pancreatic tail resection
(n¼ 1), distal pancreatectomy and splenectomy (n¼ 1)
and a pancreatic duct stent placement (n¼ 1).
In 21 of 34 patients (62%), the treatment was started
after the initial IAP episode, whereas the other 13
patients (38%) had recurrent acute pancreatitis epi-
sodes before the start of treatment. After treatment
29 patients out of 34 patients (85%) were free of recur-
rences. In the group of patients where additional diag-
nostic workup revealed an aetiology, the risk of
recurrence after treatment was 0.34 (95% CI: 0.137–
0.841) compared to the risk of recurrence without treat-
ment. In the subgroup of 50 patients with recurrent
acute pancreatitis, the recurrence rate after treatment
was 31% versus 97% in patients without treatment
(p< 0.001), the accompanying relative risk of recur-
rence in the group without treatment 23.4 (95% CI:
3.296-–165.778), compared to the group with
treatment.
Discussion
The aetiology of acute pancreatitis remains unknown
16-26% of cases. In our cohort of 1632 acute pancrea-
titis patients, 12% was idiopathic which is lower com-
pared to other studies such as the Hungarian Pancreatic
Study Group cohort that showed a rate of 16.3%.1–4
Table 5. Diagnostic work-up in patients with a single episode of idiopathic acute pancreatitis (n¼ 141).
Type of additional test
Total amount of
patients that had
additional test – no. (%)
Biliary aetiology
demonstrated – no. Other aetiology demonstrated
CT 88 (62%) 4 3 pancreatic carcinoma
2 chronic pancreatitis
1 neuroendocrine tumour
Repeat TUS 59 (42%) 10 2 pancreatic tumour
(1 combined with biliary stones)
EUS 36 (26%) 8 2 ampullary carcinoma
2 chronic pancreatitis
1 neuroendocrine tumour
MRI/MRCP 29 (21%) 4 (1 combined with
pancreas divisum)
1 pancreatic carcinoma
1 pancreas divisum
2 chronic pancreatitis
ERCP 9 (6%) 3 1 ampullary carcinoma
IgG4-testing 30 (21%) – 3 autoimmune
Total for all diagnostic tests$ 128 (91%) 22 (1 combined with
pancreas divisum)
3 pancreatic carcinoma
3 autoimmune
3 chronic pancreatitis
2 ampullary carcinoma
1 pancreas divisum
1 neuroendocrine tumour
$In case of multiple etiological factors, only the etiological factor that was treated is given in the table.
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Possibly, the strict criteria to deﬁne ‘presumed’ IAP in
our cohort, especially in regard to absence of a possible
biliary aetiology explains this lower rate. For acute
pancreatitis, current guidelines advise the diagnostic
work-up to comprise at least a thorough personal and
family history taking, laboratory tests and a TUS. As a
next step, a repeat TUS can be performed to re-assess a
potential biliary aetiology. In our cohort half of the
patients underwent a repeat TUS with a yield of
21%. Even though current guidelines advise a repeat
TUS, few studies have investigated its diagnostic yield
in IAP. Signoretti et al. retrospectively investigated the
sensitivity, speciﬁcity and accuracy for detecting a bil-
iary origin on repeat TUS in a group of 155 acute pan-
creatitis patients, of whom 85 underwent a repeat US
within 1 week after admission. They found a sensitivity
of 82%, a speciﬁcity of 75% and an overall accuracy of
78% to detect a biliary aetiology.27 However, they
investigated all acute pancreatitis patients and not spe-
ciﬁcally IAP patients, including those with a ﬁrst posi-
tive TUS giving ample explanation of why their
performance was higher compared to our study.
Overall, the diagnostic yield of 21% found in this
study, combined with the low costs, safety, and wide-
spread availability of TUS, underscore the diagnostic
worth of performing a repeat TUS.
In our study the yield of EUS was 36%, which is low
compared to other studies. Wan et al. found a diagnos-
tic yield for the aetiology of IAP of 64% for EUS in a
meta-analysis of 2,338 patients with IAP, with the most
common ﬁnding being choledocholithiasis and/or cho-
lecystolithiasis (33%).6 In a recent systematic review a
similar diagnostic yield of 62% with 37% biliary aeti-
ology was found.10 This diﬀerence is likely explained by
the fact that most studies in this meta-analysis included
patients with high serum ALT levels and/or CBD dila-
tation prior to EUS resulting in a higher a priori chance
of ﬁnding biliary stones, thereby increasing the diag-
nostic yield of EUS. In our study, a biliary aetiology
was established using additional work-up in 20% of
patients with ‘presumed’ IAP. However, in order to
exclude patients with a high likelihood of having a bil-
iary aetiology, the criteria we used to deﬁne ‘presumed’
IAP were stricter. Both patients with CBD dilatation
Table 6. Diagnostic work-up in patients with recurrent acute pancreatitis (n¼ 50).
Type of additional test
Total amount of
patients that had
additional test – no. (%)
Biliary aetiology
demonstrated – no. Other aetiology demonstrated
CT 36 (72%) 6 5 pancreatic carcinoma
1 cystic lesion (pathology showed autoimmune)
1 IPMN
Repeat TUS 38 (76%) 13 2 pancreatic tumour
EUS 26 (52%) 6 3 pancreatic carcinoma
(1 combined with biliary stones)
2 IPMN
2 chronic pancreatitis
1 pancreas divisum
MRI/MRCP 27 (54%) 5 2 chronic pancreatitis
1 pancreatic carcinoma
1 autoimmune
1 pancreas divisum
ERCP 6 (12%) – 1 pancreatic carcinoma
1 pancreas divisum
IgG4 testing 24 (52%)) – 2 autoimmune
Total for all
diagnostic tests$
48 (96%) 17 (1 combined with
pancreas divisum)
6 pancreatic carcinoma (1 combined with
biliary stones and chronic pancreatitis)
3 autoimmune (1 based on pathology
analysis of resected cystic lesion)
2 chronic pancreatitis
1 IPMN
$In case of multiple etiological factors, only the etiological factor that was treated is given in the table.
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and patients with serum ALT levels> 2ULN were
excluded. Multiple studies have shown that the likeli-
hood of a biliary aetiology is very high in these
patients.16–18 Despite these strict inclusion and exclu-
sion criteria in the current study, we found a sizable
portion of ‘presumed’ IAP patients that turned out to
have occult biliary disease, underlining the importance
and need for an additional and detailed work-up in
these patients.
The yield of MRI/MRCP (33%) was similar to other
studies. The meta-analyses by Wan et al. showed a yield
of 34% for MRI.6 Previous studies have shown that the
yield of ﬁnding microlithiasis and sludge is higher in
EUS than in MRI/MRCP.6,28 Especially in the IAP
population, where microlithiasis is considered an
important aetiological factor, many clinicians consider
EUS the preferred second diagnostic step after TUS.
In current practice, ERCP is not routinely per-
formed for diagnostic purposes due to its associated
procedural risks compared to other diagnostic modal-
ities.29 In the current study, 8% of patients did undergo
an ERCP, which was mostly performed for reasons of a
high clinical suspicion of biliary stones (i.e. jaundice,
progressive cholestasis during admission) or because
of a suspected anomaly of the papilla on EUS. In
these cases with a high clinical suspicion for pathology,
the diagnostic yield of ERCP was high (44%).
Nevertheless, this was mostly after presumptive diagno-
sis was already made with another investigational
modality which in fact constituted the indication to
perform ERCP. On that note, one might argue that
ERCP was negative in the majority of patients (56%)
in whom this invasive procedure might have been pre-
vented if, for example, a diagnostic EUS was performed
prior to ERCP.
Even though current guidelines do not advise IgG4
testing as part of the diagnostic work-up of ‘presumed’
IAP after a ﬁrst episode, surprisingly, in almost one-
third of patients (28%) in this study serum IgG4 levels
were measured. In 9% of those patients the serum IgG4
levels were elevated (i.e. 2x ULN or higher), and two of
these patients were treated with prednisone with
good response. The International Association of
Pancreatology published a consensus guideline on diag-
nostic criteria for autoimmune pancreatitis stating that
elevation in serological markers alone is not deemed
suﬃcient for the diagnosis.26 The work-up for auto-
immune pancreatitis in patients included in this study
was not uniformly performed according to guidelines.
In this study genetic counselling or genetic testing
was not performed. This might be due to patient selec-
tion prior to inclusion, as patients with a family history
of hereditary pancreatitis, know genetic mutations or
younger patients with non-alcoholic calcifying pancrea-
titis in whom testing already revealed a genetic cause
were excluded from this cohort. Omitting genetic coun-
selling might lead to misclassiﬁcation of patients with
hereditary pancreatitis as idiopathic. Therefore, in
accordance with the IAP/APA guideline clinicians
should consider genetic counselling in recurrent IAP.5
Additional work-up revealed a neoplasm in 13 (7%)
‘presumed’ IAP patients. Acute pancreatitis patients
are known to have an increased risk of harbouring pan-
creatic malignancy.30 A Danish population-based
study, perform found that the pancreatic cancer risk
was high in patients with IAP, with an adjusted
Hazard ratio of 2.52 (95% CI: 1.83–3.47) at 5-years
of follow-up.31 A previous DPSG study con-
ﬁrmed this ﬁnding. In that study, a pancreatic
cancer rate of 0.7% was found in 731 patients with a
ﬁrst episode of acute pancreatitis, and the risk was
2% in the subgroup of patients with an unknown aeti-
ology.32 In both aforementioned studies however,
the deﬁnition of IAP or ‘unknown aetiology’ was
not speciﬁed.
Most patients in our study had a single attack of
‘presumed’ IAP with a mild disease course. One-
fourth of patients had one or more recurrences, which
is comparable to previous studies.33 In a similar Dutch
cohort of 669 patients with acute pancreatitis, research-
ers found a recurrence rate of 17% overall and of 25%
in the 108 included IAP patients.34 However, in that
study the deﬁnition of IAP was not as clearly described
as in the current study, making it diﬃcult to compare
results. As expected, we found that treatment of an
underlying aetiology reduced recurrence rates.
Strengths and limitations
The current study comprises a large cohort of patients
with a ﬁrst episode of ‘presumed’ IAP, all of whom
were prospectively followed for more than 2 years,
thus making sure that late complications, aetiological
diagnoses and recurrences could be identiﬁed.
The criteria we used to deﬁne patients with ‘presumed’
IAP after an initial work-up was in accordance with the
latest literature consensus. Furthermore, the criteria
used to exclude patients with a high likelihood of
having biliary pancreatitis, alcohol-related pancreatitis
or chronic pancreatitis were more strict compared to
most other studies investigating the diagnostic work-
up of IAP.
There are also limitations to our study. First, serum
triglycerides and calcium levels were not available in all
patients. Although hypertriglyceridemia and hypercal-
cemia are considered rare causes of pancreatitis, in this
subgroup of patients with unexplained aetiology the
proportion might be higher than in the total acute pan-
creatitis population. Therefore, omitting these tests
might have led to an under-diagnosis of these
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aetiologies. Second, some caution is advised when inter-
preting the diagnostic yield of additional imaging. We
evaluated all diagnostic tests that were performed, not
only tests solely performed with the purpose of estab-
lishing an aetiology for the (recurrent) pancreatitis.
Furthermore, the ﬁnding of an aetiological factor
using a test is not deﬁnite proof that this factor is the
deﬁnite cause of the acute pancreatitis.
Conclusion
Our study shows that additional diagnostic work-up
can identify an aetiology in one-third of patients with
‘presumed’ IAP. The aetiology most commonly found
was biliary. However, in a substantial portion of
patients an underlying malignancy was detected.
Furthermore, we show that the diagnostic work-up
after a ﬁrst attack of ‘presumed’ IAP is performed
according to current guidelines in less than one-fourth
of patients. This is worrisome, as identiﬁcation of an
aetiology with subsequent treatment reduces the risk of
recurrences. In light of this observation, better guide-
line adherence is advised, i.e. a repeat TUS, if necessary
followed by either EUS or MRCP in all patients after a
ﬁrst unexplained acute pancreatitis attack.
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